Through EmpathBio, ATAI Life Sciences says it will develop “safer” MDMA derivatives for patients with PTSD and calls the Multidisciplinary Association for Psychedelic Studies' (MAPS) approach "MDMA 1.0." MAPS' executive director, Rick Doblin, says that if that's the case, ATAI is "MDMA 0.5."

Since COMPASS Pathways filed for a controversial psilocybin patent in 2018, Usona Institute has consistently placed its research findings in the public domain.

MAPS claims the most sustainable way to produce commercial MDMA is through the use of petrochemical feedstocks.

LSD chemist and longtime drug war prisoner, William Leonard Pickard, was officially released from prison on July 27, 2020. Pickard had been locked down since 2000 and was slated to serve two life sentences without the possibility of parole.

"I want nothing to do with those kinds of folks who want to decriminalize psychedelics,” Rahn told Forbes."

Field Trip Ventures leads the charge to use “psychedelic” as a marketing buzzword for any kind of niche therapy.

Contributors to the Daily Psychedelic Video platform gather on Zoom to bless the opening of the Psychedelic Video Museum: a collection of ten years’ worth of their shared visions.

'Debbie and Doug Drop Acid in the Desert' director, Scott Brown, talks mind-altering drugs, creating psychedelic visual effects, and dealing with depression.

Almost all clinical psychedelic drug research is being affected in some way or another by COVID-19. But, response measures vary from one organization to the next.

“The Corona Virus is a necessary purge of what is no longer in resonance,” Trinity de Guzman wrote in a recent email to his followers.